Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: A randomized, controlled, Phase III trialAmaia Hervás, Brigitte Robertson, Vanja Sikirica et al.|European Neuropsychopharmacology|2014Cited by 79
Extended‐release guanfacine hydrochloride in 6–17‐year olds with ADHD: a randomised‐withdrawal maintenance of efficacy studyJeffrey H. Newcorn, Brigitte Robertson, Valerie Harpin et al.|Journal of Child Psychology and Psychiatry|2016Cited by 37
EPA-0666 – Long-term maintenance of efficacy of extended-release guanfacine hydrochloride (GXR) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD): double-blind, placebo-controlled, multicentre, phase 3 randomized withdrawal studyJeffrey H. Newcorn, Brigitte Robertson, Valerie Harpin et al.|European Psychiatry|2014Cited by 5
EPA-0685 – Guanfacine XR (GXR) for children and adolescents with attention-deficit/hyperactivity disorder (ADHD): phase 3, randomized, double-blind, multicenter, placebo- and active-reference studyAmaia Hervás, Brigitte Robertson, Mats Johnson et al.|European Psychiatry|2014Cited by 3